Therapeutic uses against cancer

Pitson, S. M. Vadas, M. A. Xia, P Moretti, P. A. Leclercq, T. Sutherland, C. Methods of modulating sphingosine kinase signaling or localization, sphingosine kinase sequence variants, and therapeutic uses against cancer and inflammation. PCX Int. Appl. WO 2005123115, 2005 Chem. Abstr. 2005,144, 83059. 

The ground-breaking development of monoclonal antibodies by Kohler and Milstein [21] initiated the development of antibody-mediated therapeutics for cancer. Because of their unique specificity, MAb were predicted to become the magic bullets in the battle against cancer. Over the last two and a half decades MAbs have moved from clone to clinic for the treatment of various malignancies. Several MAbs are currently entering clinical trials and should appear on the market in the next few years. The first MAb for cancer therapy was approved in the US in 1997. 

In summary, we should look forward to successful clinical reports of siRNA cancer therapies and results from ongoing clinical trials will help us in further understanding and developing siRNA-based therapeutics against cancer in the near future. 

---